Global Gastrointestinal Diseases Market – Industry Analysis and Forecast (2017 -2026) – by Drug Category (GIT Anti-Inflammatory, Antacid & Anti-Ulcerant and Integrated Anesthesia Workstation) and by Geography (North America, Europe, Asia Pacific, Middle East & Africa and Latin America)

Global Gastrointestinal Diseases Market – Industry Analysis and Forecast (2017 -2026) – by Drug Category (GIT Anti-Inflammatory, Antacid & Anti-Ulcerant and Integrated Anesthesia Workstation) and by Geography (North America, Europe, Asia Pacific, Middle East & Africa and Latin America)

Market Scenario

Gastrointestinal Diseases Market valued USD 17.59 Billion in 2017 and expected to reach USD 21.67 Billion by 2026, at a CAGR of 2.64%. Gastrointestinal Diseases Market The market for Gastrointestinal Diseases is primarily depended on increasing life expectancy and improved accessibility to healthcare facilities worldwide. Various factors to be considered for Gastrointestinal Diseases include continuous consideration by analysis of patient’s oxygenation, ventilation, blood circulation, and body temperature. Report includes assessment of Global Gastrointestinal Diseases Market definition along with the identification of key players and analysis of their strategies, complete quantitative analysis of the industry from 2017 to 2026 to enable the stakeholders to capitalize on the prevailing market opportunities, market analysis and comprehensive segmentation with respect to the drug category and geography to assist in strategic business planning. APAC is expected to register the highest growth rate in Gastrointestinal Diseases Market during forecast period. APAC is expected to lead the Global Gastrointestinal Diseases Market during the forecast period. Growing investments and funding in the field of life science research and advanced therapies for the treatment of gastrointestinal diseases in developing nations such as China and India will fuel the Global Gastrointestinal Diseases Market in APAC region.

Scope of the Report:

Global Gastrointestinal Diseases Market, By Drug Category:

• Antacid & Anti-Ulcerant • GIT Anti-inflammatory • Antiemetic, Anti-diarrhea • Other GIT Therapeutics

Global Gastrointestinal Diseases Market, By Geography:

• North America • Europe • Asia Pacific • Middle East and Africa • Latin America

Key players in Global Gastrointestinal Diseases Market are:

• AstraZeneca • Shire • Valeant (Salix Pharmaceuticals) • Takeda Pharmaceutical Company Limited • Eisai Co. Ltd. • Allergan • Johnson & Johnson Private Limited Available Customization Maximize Market Research offers customization of report and scope of the report as per the specific requirement of our client. Dental Equipment Market

Table of Contents

Global Gastrointestinal Diseases market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Gastrointestinal Diseases market Size, by Market Value (US$ Bn ) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Gastrointestinal Diseases market Analysis and Forecast 6.1. Global Gastrointestinal Diseases market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Gastrointestinal Diseases market Analysis and Forecast, by Drug Category 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Gastrointestinal Diseases market Value Share Analysis, by Drug Category 7.4. Global Gastrointestinal Diseases market Size (US$ Bn ) Forecast, by Drug Category 7.5. Global Gastrointestinal Diseases market Analysis, by Drug Category 7.6. Global Gastrointestinal Diseases market Attractiveness Analysis, by Drug Category 8. Global Gastrointestinal Diseases market Analysis, by Region 8.1. Global Gastrointestinal Diseases market Value Share Analysis, by Region 8.2. Global Gastrointestinal Diseases market Size (US$ Bn ) Forecast, by Region 8.3. Global Gastrointestinal Diseases market Attractiveness Analysis, by Region 9. North America Gastrointestinal Diseases market Analysis 9.1. Key Findings 9.2. North America Gastrointestinal Diseases market Overview 9.3. North America Gastrointestinal Diseases market Value Share Analysis, by Drug Category 9.4. North America Gastrointestinal Diseases market Forecast, by Drug Category 9.4.1. Antacid & Anti-Ulcerant 9.4.2. GIT Anti-inflammatory 9.4.3. Antiemetic 9.4.4. Anti-diarrhoea 9.4.5. Other 9.5. North America Gastrointestinal Diseases market Value Share Analysis, by Country 9.6. North America Gastrointestinal Diseases market Forecast, by Country 9.6.1. U.S. 9.6.2. Canada 9.7. North America Gastrointestinal Diseases market Analysis, by Country 9.8. U.S. Gastrointestinal Diseases market Forecast, by Drug Category 9.8.1. Antacid & Anti-Ulcerant 9.8.2. GIT Anti-inflammatory 9.8.3. Antiemetic 9.8.4. Anti-diarrhoea 9.8.5. Other 9.9. Canada Gastrointestinal Diseases market Forecast, by Drug Category 9.9.1. Antacid & Anti-Ulcerant 9.9.2. GIT Anti-inflammatory 9.9.3. Antiemetic 9.9.4. Anti-diarrhoea 9.9.5. Other 9.10. North America Gastrointestinal Diseases market Attractiveness Analysis 9.10.1. By Drug Category 9.11. PEST Analysis 9.12. Key Trends 9.13. Key Developments 10. Europe Gastrointestinal Diseases market Analysis 10.1. Key Findings 10.2. Europe Gastrointestinal Diseases market Overview 10.3. Europe Gastrointestinal Diseases market Value Share Analysis, by Drug Category 10.4. Europe Gastrointestinal Diseases market Forecast, by Drug Category 10.4.1. Antacid & Anti-Ulcerant 10.4.2. GIT Anti-inflammatory 10.4.3. Antiemetic 10.4.4. Anti-diarrhoea 10.4.5. Other 10.5. Europe Gastrointestinal Diseases market Value Share Analysis, by Country 10.6. Europe Gastrointestinal Diseases market Forecast, by Country 10.6.1. Germany 10.6.2. U.K. 10.6.3. France 10.6.4. Italy 10.6.5. Spain 10.6.6. Rest of Europe 10.7. Europe Gastrointestinal Diseases market Analysis, by Country 10.8. Germany Gastrointestinal Diseases market Forecast, by Drug Category 10.8.1. Antacid & Anti-Ulcerant 10.8.2. GIT Anti-inflammatory 10.8.3. Antiemetic 10.8.4. Anti-diarrhoea 10.8.5. Other 10.9. U.K. Gastrointestinal Diseases market Forecast, by Drug Category 10.9.1. Antacid & Anti-Ulcerant 10.9.2. GIT Anti-inflammatory 10.9.3. Antiemetic 10.9.4. Anti-diarrhoea 10.9.5. Other 10.10. France Gastrointestinal Diseases market Forecast, by Drug Category 10.10.1. Antacid & Anti-Ulcerant 10.10.2. GIT Anti-inflammatory 10.10.3. Antiemetic 10.10.4. Anti-diarrhoea 10.10.5. Other 10.11. Italy Gastrointestinal Diseases market Forecast, by Drug Category 10.11.1. Antacid & Anti-Ulcerant 10.11.2. GIT Anti-inflammatory 10.11.3. Antiemetic 10.11.4. Anti-diarrhoea 10.11.5. Other 10.12. Spain Gastrointestinal Diseases market Forecast, by Drug Category 10.12.1. Antacid & Anti-Ulcerant 10.12.2. GIT Anti-inflammatory 10.12.3. Antiemetic 10.12.4. Anti-diarrhoea 10.12.5. Other 10.13. Rest of Europe Gastrointestinal Diseases market Forecast, by Drug Category 10.13.1. Antacid & Anti-Ulcerant 10.13.2. GIT Anti-inflammatory 10.13.3. Antiemetic 10.13.4. Anti-diarrhoea 10.13.5. Other 10.14. Europe Gastrointestinal Diseases market Attractiveness Analysis 10.14.1. By Drug Category 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Asia Pacific Gastrointestinal Diseases market Analysis 11.1. Key Findings 11.2. Asia Pacific Gastrointestinal Diseases market Overview 11.3. Asia Pacific Gastrointestinal Diseases market Value Share Analysis, by Drug Category 11.4. Asia Pacific Gastrointestinal Diseases market Forecast, by Drug Category 11.4.1. Antacid & Anti-Ulcerant 11.4.2. GIT Anti-inflammatory 11.4.3. Antiemetic 11.4.4. Anti-diarrhoea 11.4.5. Other 11.5. Asia Pacific Gastrointestinal Diseases market Value Share Analysis, by Country 11.6. Asia Pacific Gastrointestinal Diseases market Forecast, by Country 11.6.1. China 11.6.2. India 11.6.3. Japan 11.6.4. ASEAN 11.6.5. Rest of Asia Pacific 11.7. Asia Pacific Gastrointestinal Diseases market Analysis, by Country 11.8. China Gastrointestinal Diseases market Forecast, by Drug Category 11.8.1. Antacid & Anti-Ulcerant 11.8.2. GIT Anti-inflammatory 11.8.3. Antiemetic 11.8.4. Anti-diarrhoea 11.8.5. Other 11.9. India Gastrointestinal Diseases market Forecast, by Drug Category 11.9.1. Antacid & Anti-Ulcerant 11.9.2. GIT Anti-inflammatory 11.9.3. Antiemetic 11.9.4. Anti-diarrhoea 11.9.5. Other 11.10. Japan Gastrointestinal Diseases market Forecast, by Drug Category 11.10.1. Antacid & Anti-Ulcerant 11.10.2. GIT Anti-inflammatory 11.10.3. Antiemetic 11.10.4. Anti-diarrhoea 11.10.5. Other 11.11. ASEAN Gastrointestinal Diseases market Forecast, by Drug Category 11.11.1. Antacid & Anti-Ulcerant 11.11.2. GIT Anti-inflammatory 11.11.3. Antiemetic 11.11.4. Anti-diarrhoea 11.11.5. Other 11.12. Rest of Asia Pacific Gastrointestinal Diseases market Forecast, by Drug Category 11.12.1. Antacid & Anti-Ulcerant 11.12.2. GIT Anti-inflammatory 11.12.3. Antiemetic 11.12.4. Anti-diarrhoea 11.12.5. Other 11.13. Asia Pacific Gastrointestinal Diseases market Attractiveness Analysis 11.13.1. By Drug Category 11.14. PEST Analysis 11.15. Key Trends 11.16. Key Developments 12. Middle East & Africa Gastrointestinal Diseases market Analysis 12.1. Key Findings 12.2. Middle East & Africa Gastrointestinal Diseases market Overview 12.3. Middle East & Africa Gastrointestinal Diseases market Value Share Analysis, by Drug Category 12.4. Middle East & Africa Gastrointestinal Diseases market Forecast, by Drug Category 12.4.1. Antacid & Anti-Ulcerant 12.4.2. GIT Anti-inflammatory 12.4.3. Antiemetic 12.4.4. Anti-diarrhoea 12.4.5. Other 12.5. Middle East & Africa Gastrointestinal Diseases market Value Share Analysis, by Country 12.6. Middle East & Africa Gastrointestinal Diseases market Forecast, by Country 12.6.1. GCC 12.6.2. South Africa 12.6.3. Rest of Middle East & Africa 12.7. Middle East & Africa Gastrointestinal Diseases market Analysis, by Country 12.8. GCC Gastrointestinal Diseases market Forecast, by Drug Category 12.8.1. Antacid & Anti-Ulcerant 12.8.2. GIT Anti-inflammatory 12.8.3. Antiemetic 12.8.4. Anti-diarrhoea 12.8.5. Other 12.9. South Africa Gastrointestinal Diseases market Forecast, by Drug Category 12.9.1. Antacid & Anti-Ulcerant 12.9.2. GIT Anti-inflammatory 12.9.3. Antiemetic 12.9.4. Anti-diarrhoea 12.9.5. Other 12.10. Rest of Middle East & Africa Gastrointestinal Diseases market Forecast, by Drug Category 12.10.1. Antacid & Anti-Ulcerant 12.10.2. GIT Anti-inflammatory 12.10.3. Antiemetic 12.10.4. Anti-diarrhoea 12.10.5. Other 12.11. Middle East & Africa Gastrointestinal Diseases market Attractiveness Analysis 12.11.1. By Drug Category 12.12. PEST Analysis 12.13. Key Trends 12.14. Key Developments 13. South America Gastrointestinal Diseases market Analysis 13.1. Key Findings 13.2. South America Gastrointestinal Diseases market Overview 13.3. South America Gastrointestinal Diseases market Value Share Analysis, by Drug Category 13.4. South America Gastrointestinal Diseases market Forecast, by Drug Category 13.4.1. Antacid & Anti-Ulcerant 13.4.2. GIT Anti-inflammatory 13.4.3. Antiemetic 13.4.4. Anti-diarrhoea 13.4.5. Other 13.5. South America Gastrointestinal Diseases market Value Share Analysis, by Country 13.6. South America Gastrointestinal Diseases market Forecast, by Country 13.6.1. Brazil 13.6.2. Mexico 13.6.3. Rest of South America 13.7. South America Gastrointestinal Diseases market Analysis, by Country 13.8. Brazil Gastrointestinal Diseases market Forecast, by Drug Category 13.8.1. Antacid & Anti-Ulcerant 13.8.2. GIT Anti-inflammatory 13.8.3. Antiemetic 13.8.4. Anti-diarrhoea 13.8.5. Other 13.9. Mexico Gastrointestinal Diseases market Forecast, by Drug Category 13.9.1. Antacid & Anti-Ulcerant 13.9.2. GIT Anti-inflammatory 13.9.3. Antiemetic 13.9.4. Anti-diarrhoea 13.9.5. Other 13.10. Rest of South America Gastrointestinal Diseases market Forecast, by Drug Category 13.10.1. Antacid & Anti-Ulcerant 13.10.2. GIT Anti-inflammatory 13.10.3. Antiemetic 13.10.4. Anti-diarrhoea 13.10.5. Other 13.11. South America Gastrointestinal Diseases market Attractiveness Analysis 13.11.1. By Drug Category 13.12. PEST Analysis 13.13. Key Trends 13.14. Key Developments 14. Company Profiles 14.1. Market Share Analysis, by Company 14.2. Competition Matrix 14.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 14.2.2. Market Consolidation 14.2.2.1. M&A by Regions, Investment and Applications 14.2.2.2. M&A Key Players, Forward Integration and Backward Integration 14.3. Company Profiles: Key Players 14.3.1. Amazon 14.3.1.1. Company Overview 14.3.1.2. Financial Overview 14.3.1.3. Product Portfolio 14.3.1.4. Business Strategy 14.3.1.5. Recent Developments 14.3.1.6. Development Footprint 14.3.2. Shire 14.3.3. Valeant (Salix Pharmaceuticals) 14.3.4. Takeda Pharmaceutical Company Limited 14.3.5. Eisai Co., Ltd. 14.3.6. Allergan 14.3.7. Johnson & Johnson Private Limited 15. Primary Key Insights

Inquiry Before Buying

Request Sample

About This Report

Report ID 304
Published Date Nov 2017
Contact Us
Call Now